Johnson & Johnson unveils first clinical data for prostate cancer drug JNJ-6143 at ESMO 2026

By Public Technologies
  • Johnson & Johnson will present more than 25 solid-tumor abstracts at the 2026 ESMO Congress, including first clinical results for JNJ-6143.
  • The investigational oral prostate cancer drug’s safety and efficacy findings will guide dose selection following the December 2025 acquisition of Halda Therapeutics.
  • Late-breaking Phase 3 PROTEUS results will assess perioperative Erleada treatment against surgery alone in high-risk localized or locally advanced prostate cancer.
  • Initial OrigAMI-4 findings show encouraging tumor responses with Rybrevant Faspro combined with pembrolizumab and carboplatin in first-line recurrent or metastatic head-and-neck cancer.
  • A separate indirect comparison found improved survival with Rybrevant Faspro monotherapy versus real-world therapies in previously treated head-and-neck cancer; results await presentation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.